Airway immune mediator levels during asthma-like symptoms in young children and their possible role in response to azithromycin

Autor: Christian J. Carlsson, Bo L. Chawes, Susanne Brix Pedersen, Jakob Stokholm, Klaus Bønnelykke, Hans Bisgaard, Ni Wang, Morten Arendt Rasmussen
Rok vydání: 2020
Předmět:
Zdroj: Carlsson, C J, Rasmussen, M A, Pedersen, S B, Wang, N, Stokholm, J, Chawes, B L, Bønnelykke, K & Bisgaard, H 2021, ' Airway immune mediator levels during asthma-like symptoms in young children and their possible role in response to azithromycin ', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, no. 6, pp. 1754-1764 . https://doi.org/10.1111/all.14651
Carlsson, C J, Rasmussen, M A, Pedersen, S B, Wang, N, Stokholm, J, Chawes, B L, Bønnelykke, K & Bisgaard, H 2021, ' Airway immune mediator levels during asthma-like symptoms in young children and their possible role in response to azithromycin ', Allergy, vol. 76, no. 6, pp. 1754-1764 . https://doi.org/10.1111/all.14651
ISSN: 1398-9995
DOI: 10.1111/all.14651
Popis: Background: Asthma-like symptoms in young children are orchestrated by the local airway immune response, but current knowledge largely relies on in vitro airway models. Azithromycin has been shown to reduce the duration of episodes with asthma-like symptoms, but efficacy may depend on the individual child's immune response. Objectives: To investigate in vivo upper airway immune mediator levels during episodes with asthma-like symptoms in young children and their ability to predict the clinical response to azithromycin treatment. Methods: A total of 535 children aged 0-3 years from the Copenhagen Prospective Studies of Asthma in Childhood-2010 mother-child cohort were examined for immune mediator levels in samples of nasal epithelial lining fluid during episodes with asthma-like symptoms as well as in the asymptomatic state. In a sub-study, children with recurrent asthma-like symptoms were randomized to either a 3-day course of oral azithromycin (10 mg/kg; n = 32) or placebo (n = 38). In the current study, we compared the pretreatment immune mediator levels with the clinical response to treatment with azithromycin in an exploratory post hoc analysis. Results: The immune mediator concentrations during vs outside episodes were significantly upregulated for IFN-ɣ (ratio 1.73), TNF-α (ratio 2.05), IL-1β (ratio 1.45), IL-10 (ratio 1.97), while CCL22 (ratio 0.65) was downregulated. Low levels of TNF-α and IL-10 and high levels of CCL22 predicted better treatment response to azithromycin (P-values
Databáze: OpenAIRE
Externí odkaz: